Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.» Read More
Shares of Dendreon shot up after a panel of FDA advisers voted Provenge is both safe and effective in treating advanced prostate cancer.
Shares of Dendreon are up about 250% in pre-market trading after a panel of FDA advisers voted Provenge is both safe and effective in treating advanced prostate cancer.
Shares of pharmaceutical firm Dendreon leaped on Wednesday following a CNBC report about a planned Thursday Food and Drug Administration hearing that could determine the fate of a prostate cancer drug from the company.
The Southern California farm that grew the green onions that were first linked to and then cleared in last year's E. coli outbreak has filed a libel lawsuit against Taco Bell.
The test, called the Xpert EV test, can detect the condition in 2.5 hours compared with other products that can take as long as a week, the FDA said.
U.S. health regulators have approved GlaxoSmithKline's pill Tykerb for patients with advanced breast cancer after other treatments have failed, a company spokeswoman said on Tuesday.
J.P. Garnier, GlaxoSmithKline's chief executive officer, told CNBC's "Squawk Box" Wednesday that he expects to make the company's new drug for advanced breast cancer available to U.S. patients "within a few days."
The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.
Gen-Probe has won U.S. approval to sell its Procleix blood test to detect the West Nile virus, a Food and Drug Administration spokeswoman said Friday.
A judge on Tuesday sentenced former Food and Drug Administration chief Lester Crawford to three years' supervised probation with fines of roughly $90,000 for lying about stocks he owned in companies regulated by his agency.
Federal health advisers recommended Tuesday that the government approve the first bird flu vaccine as a stopgap measure, despite evidence it wouldn't protect most people.
Genentech shares traded lower after data from a clinical trial indicated that a lower dosage of the blockbuster cancer drug Avastin was as effective as the standard dose for lung cancer patients.
Genentech's asthma drug Xolair should carry the strongest warning possible about the drug's risk of a serious reaction known as anaphylaxis, U.S. health regulators said today.
GlaxoSmithKline has won FDA approval to sell the formerly prescription-only diet drug Xenical over-the-counter. The drug can help people lose, on average, about six pounds. It'll be called "Alli" (pronounced like "ally"). GSK will split the profits with Roche, which owns prescription Xenical. ... An analyst says Alli could have peak sales of $100 million to $300 million, which would be a blockbuster by OTC-drug standards.
A protest in Washington may underscore public concerns about cloning, but the food industry is in no rush to bring cloned food to market. The FDA says cloning produces no health hazards and doesn't plan to require special labels for food derived from cloned animals.
Big Pharma is facing a dose of big reforms proposed by Congress. Some heavy-hitters are pushing for more oversight of the drug industry by strengthening the authority of the FDA. Do we need increased regulations and should the FDA be given more authority? Those were the issues at the heart of a heated debate today on CNBC’s “Morning Call.”
The government is considering setting higher standards for birth control drugs used by millions, saying that newer pills appear to be less effective at preventing pregnancy than those approved decades ago.
While on Capitol Hill the new Congress begins to take on the pharmaceuticals industry, the healthcare investment community is holding its annual confab in the hills of San Francisco--House Speaker Nancy Pelosi's home district. I'm at the 25th Annual JPMorgan Healthcare Conference at the Westin St. Francis on Union Square. The four-day event is just getting started, but the halls are...
The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.
Two lupus patients died from a rare brain infection after taking the Genentech and Biogen drug Rituxan, U.S. health officials said in an advisory issued Monday.